Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Clinical trial NCT05840211 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05840211
Sponsor: Gilead Sciences
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Locally Advanced or Unresectable Metastatic Breast Cancer Stage IV Breast Cancer

Start date: 2023-05-08
Primary completion: 2028-04-01
Enrollment: 654

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.